Treatment of an acquired coagulopathy with recombinant activated factor VII in a damage-control patient

Military Medicine

Volumn 170, Issue 4, 2005, Pages 287-290

  Holcomb, John B ^a,b,c   Hoots, Keith ^a   Moore, Fredrick A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE;

ADOLESCENT; ARM AMPUTATION; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DEBRIDEMENT; DOSE RESPONSE; ERYTHROCYTE CONCENTRATE; HEMOPERITONEUM; HUMAN; HYPOTHERMIA; INTENSIVE CARE; KIDNEY HEMORRHAGE; MALE; NEPHRECTOMY; RESUSCITATION; RETROPERITONEAL HEMATOMA; SPLEEN INJURY; SPLENECTOMY; TRAFFIC ACCIDENT; TRAUMATIC AMPUTATION;

EID: 17444364114     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.170.4.287     Document Type: Article

References (55)

1. Hedner U, Kisiel W: Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-41.
2. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA: Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
3. Hedner U, Erhardtsen E: Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann Med 2000; 32(Suppl 1): 68-72.
4. Hedner U, Erhardtsen E: Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
5. Martinowitz U, Holcomb JB, Pusateri AE, et al: Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-9.
6. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K: The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 2002; 53: 252-7.
7. Lynn M, Jerokhimov I, Jewelewicz D, et al: Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study. J Trauma 2002; 52: 703-7.
8. Sondeen JL, Pusateri AE, Hedner U, Yantis LD, Holcomb JB: Recombinant factor VIIa strengthens the clot in uncontrolled aortic hemorrhage. Shock 2004; 22: 163-8.
9. Jeroukhimov I, Jewelewicz D, Zaias J, et al: Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma 2002; 53: 1053-7.
10. Schreiber MA, Holcomb JB, Hedner U, et al: The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries. J Am Coll Surg 2003; 196: 691-7.
11. Friederich PW, Geerdink MG, Spataro M, et al: The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S129-32.
12. Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B: Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997; 42: 857-61.
13. Rotondo MF, Zonies DH: The damage control sequence and underlying logic. Surg Clin North Am 1997; 77: 761-77.
14. Shapiro MB, Jenkins DH, Schwab CW, Rotondo MF: Damage control: collective review. J Trauma 2000; 49: 969-78.
15. Wudel JH, Morris JA Jr, Yates K, Wilson A, Bass SM: Massive transfusion: outcome in blunt trauma patients. J Trauma 1991; 31: 1-7.
16. Hoyt DB, Bulger EM, Knudson MM, et al: Death in the operating room: an analysis of a multi-center experience. J Trauma 1994; 37: 426-32.
17. Heckbert SR, Vedder NB, Hoffman W, et al: Outcome after hemorrhagic shock in trauma patients. J Trauma 1998; 45: 545-9.
18. Franklin GA, Boaz PW, Spain DA, Lukan JK, Carrillo EH, Richardson JD: Pre-hospital hypotension as a valid indicator of trauma team activation. J Trauma 2000; 48: 1034-7.
19. Sauaia A, Moore FA, Moore EE, et al: Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-93.
20. Gentilello LM, Jurkovich GJ, Stark MS, Hassantash SA, O'Keefe GE: Is hypothermia in the victim of major trauma protective or harmful? A randomized, prospective study. Ann Surg 1997; 226: 439-47.
21. Kuhls DA, Malone DL, McCarter RJ, Napolitano LM: Predictors of mortality in adult trauma patients: the Physiologic Trauma Score is equivalent to the Trauma and Injury Severity Score. J Am Coll Surg 2002; 194: 695-704.
22. Armand R, Hess JR: Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17: 223-31.
23. Holcomb J, Pusateri A, MacPhee M, Hess J: New technologies in hemorrhage control. Curr Opin Crit Care 1997; 3: 488-93.
24. Rapaport SI, Rao LV: The tissue factor pathway: how it has become a "prima ballerina." Thromb Haemost 1995; 74: 7-17.
25. Meng ZH, Wolberg AS, Monroe DM, Hoffman M: The effect of temperature and pH on the activity of FVIIa: implications for the efficacy of high-dose FVIIa in hypothermic and acidotic patients. J Trauma 2003; 50: 721-9.
26. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
27. Martinowitz U, Kenet G, Segal E, et al: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8.
28. O'Neill PA, Bluth M, Gloster ES, et al: Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400-5.
29. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E: Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49: S15-20.
30. Dutton RP, Hess JR, Scalea TM: Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003; 15: 184-8.
31. Dutton RP, McCunn M, Hyder M, et al: Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57: 709-19.
32. Lin J, Hanigan WC, Tarantino M, Wang J: The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98: 737-40.
33. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003; 53: 34-8.
34. Bernstein DE, Jeffers L, Erhardtsen E, et al: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-7.
35. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D: Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28: 405-7.
36. White B, McHale J, Ravi N, et al: Successful use of recombinant FVIIa (NovoSeven) in the management of intractable post-surgical intra-abdominal hemorrhage. Br J Haematol 1999; 107: 677-8.
37. Al Douri M, Shafi T, Al Khudairi D, et al: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S121-7.
38. Moscardo F, Perez F, de la Rubia J, et al: Successful treatment of severe intraabdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114: 174-6.
39. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S. Hathirat P: Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S101-5.
40. Hendriks HG, Meijer K, de Wolf JT, et al: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71: 402-5.
41. Hicks K, Peng D, Gajewski JL: Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-8.
42. Naik VN, Mazer CD, Latter DA, Teitel JM, Hare GM: Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 2003; 50: 599-602.
43. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U: The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9: 741-8.
44. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC: Postinjury multiple organ failure: a bimodal phenomenon. J Trauma 1996; 40: 501-10.
45. Reed RL II, Johnson TD, Hudson JD, Fischer RP: The disparity between hypothermic coagulopathy and clotting studies. J Trauma 1992; 33: 465-70.
46. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF: Treatment of severe acute respiratory distress syndrome: a final report on a phase 1 study. Am Surg 2001; 67: 377-82.
47. Vasquez Y, Williams CH, Hardaway RM: Effect of urokinase on disseminated intravascular coagulation. J Appl Physiol 1998; 85: 1421-8.
48. Hardaway RM, Williams CH, Vasquez Y: Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost 2001; 27: 577-83.
49. Hedner U: NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11(Suppl 1): S107-11.
50. Hedner U: Reported serious adverse events during the use of rFVIIa. In: Recombinant Factor VIIa: Update on Clinical Experiences: International Workshop on NovoSeven, April 24, 1998. Frankfurt, Germany, International Workshop on NovoSeven, 1998.
51. Peerlinck K, Vermylen J: Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
52. Roberts HR: Recombinant factor VIIa (NovoSeven) and the safety of treatment. Semin Hematol 2001; 38(Suppl 12): 48-50.
53. Hess JR, Thomas MJ: Blood use in war and disaster: lessons from the past century. Transfusion 2003; 43: 1622-33.
54. Friederich PW, Henny CP, Messelink EJ, et al: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003: 361: 201-5.
55. Boffart KD, et al: Preliminary first report on rFVIIa as adjunctive for bleeding control in major trauma: a randomized placebo-controlled trial. Presented at the 6th World Congress on Trauma, Inflammation and Sepsis, March 2-6, 2004, Munich, Germany.